Agreement - April 7, 2021
Nanoform signs agreement with Nacuity Pharmaceuticals
Nanoform Finland and Nacuity Pharmaceuticals, a Texas-based clinical stage pharmaceutical company, have signed a Technology Proof of Concept agreement, with compensation on standard commercial terms. This will apply Nanoform’s nanoparticle CESS technology to enhance ophthalmic drug delivery of Nacuity’s NPI-001 and NPI-002 drug candidates. This work will explore the feasibility of the patented CESS process […]
Collaboration - February 10, 2021
Nanoform and Herantis sign Biologics Proof of Concept Agreement
Nanoform Finland and Herantis Pharma have announced that they have signed a Biologics Proof of Concept Agreement for formulation Proof of Concept projects (PoCs) aiming to enhance nasal drug delivery to the brain of Herantis’ CDNF therapies for Parkinson’s disease using Nanoform’s biological nanoparticle technology. The agreed and non-exclusive collaboration is intended to assess the […]
Clinical Trials - January 26, 2021
Positive interim results from Nanoform study
Nanoform has announced positive interim results from its clinical study. The faster absorption data implies that small particles can indeed be powerful, states the company in its press release. Phase I trial Nanoform has received interim study results related to its Phase 1, Single-Centre, Part Crossover, Open-Label, Partially-Randomised Study Designed to Evaluate the Pharmacokinetic (PK) […]
Clinical Trials - January 8, 2021
First dosing of nanoformed drug successfully accomplished
Nanoform has announced that the first full cohort of twelve healthy volunteers has during the weekend at Quotient Sciences’ facilities in Nottingham, UK, been successfully dosed in the first ever phase 1 human trial of a nanoformed drug candidate using Nanoform’s CESS technology. Results are expected before the end of Q2/2021. Nanoform has now achieved […]
Agreement - December 21, 2020
Nanoform and Herantis sign a letter of intent to collaborate
Nanoform Finland and Herantis Pharma have signed a letter of intent to collaborate to seek to enhance nasal drug delivery to the brain of Herantis’ CDNF and xCDNF therapies (Parkinson’s disease) using Nanoform’s biological nanoparticle technology. The planned and non-exclusive collaboration is intended to assess the utility of Nanoform’s latest platform technology for biologic drugs. […]
Biotech Business - November 30, 2020
Nanoform launches technology for biologics
Nanoform Finland has announced a technology that can form biological nanoparticles as small as 50 nm and announced a new near-term business target for 2021 to deliver its first biologics Proof of Concept project for this new technology with a pharmaceutical or biotech partner. As drug molecules become more complex so do the options to […]
